Literature DB >> 25097040

HRAS mutations are frequent in inverted urothelial neoplasms.

Andrew S McDaniel1, Yali Zhai1, Kathleen R Cho2, Saravana M Dhanasekaran3, Jeffrey S Montgomery4, Ganesh Palapattu4, Javed Siddiqui3, Todd Morgan4, Ajjai Alva5, Alon Weizer4, Cheryl T Lee4, Arul M Chinnaiyan6, Michael J Quist7, Catherine S Grasso7, Scott A Tomlins8, Rohit Mehra9.   

Abstract

Inverted urothelial papilloma (IUP) is an uncommon neoplasm of the urinary bladder with distinct morphologic features. Studies regarding the role of human papillomavirus (HPV) in the etiology of IUP have provided conflicting evidence of HPV infection. In addition, little is known regarding the molecular alterations present in IUP or other urothelial neoplasms, which might demonstrate inverted growth pattern like low-grade or high-grade urothelial carcinoma (UCA). Here, we evaluated for the presence of common driving somatic mutations and HPV within a cohort of IUPs, (n = 7) noninvasive low-grade papillary UCAs with inverted growth pattern (n = 5), and noninvasive high-grade papillary UCAs with inverted growth pattern (n = 8). HPV was not detected in any case of IUP or inverted UCA by either in situ hybridization or by polymerase chain reaction. Next-generation sequencing identified recurrent mutations in HRAS (Q61R) in 3 of 5 IUPs, described for the first time in this neoplasm. Additional mutations of Ras pathway members were detected including HRAS, KRAS, and BRAF. The presence of Ras pathway member mutations at a relatively high rate suggests this pathway may contribute to pathogenesis of inverted urothelial neoplasms. In addition, we did not find any evidence supporting a role for HPV in the etiology of IUP.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HRAS; Human papilloma virus; Inverted urothelial papillomas; Next-generation sequencing

Mesh:

Substances:

Year:  2014        PMID: 25097040      PMCID: PMC4241848          DOI: 10.1016/j.humpath.2014.06.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  34 in total

Review 1.  Biomarkers in bladder cancer: translational and clinical implications.

Authors:  Liang Cheng; Darrell D Davison; Julia Adams; Antonio Lopez-Beltran; Lisha Wang; Rodolfo Montironi; Shaobo Zhang
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-29       Impact factor: 6.312

2.  Prevalence of six types of human papillomavirus in inverted papilloma and papillary transitional cell carcinoma of the bladder: an evaluation by polymerase chain reaction.

Authors:  K W Chan; K Y Wong; G Srivastava
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

3.  Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection.

Authors:  Elen B Blochin; Kay J Park; Satish K Tickoo; Victor E Reuter; Hikmat Al-Ahmadie
Journal:  Mod Pathol       Date:  2012-07-06       Impact factor: 7.842

4.  Natural history of urothelial inverted papilloma.

Authors:  Ming-Tse Sung; Gregory T Maclennan; Antonio Lopez-Beltran; Rodolfo Montironi; Liang Cheng
Journal:  Cancer       Date:  2006-12-01       Impact factor: 6.860

5.  Telomere shortening distinguishes inverted urothelial neoplasms.

Authors:  Sean R Williamson; Shaobo Zhang; Antonio Lopez-Beltran; Rodolfo Montironi; Mingsheng Wang; Liang Cheng
Journal:  Histopathology       Date:  2013-02-05       Impact factor: 5.087

6.  Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract.

Authors:  Matthias Eiber; Johanna M M van Oers; Ellen C Zwarthoff; Theo H van der Kwast; Oehler Ulrich; Burkhard Helpap; Stephan Stoerkel; Hagen Blaszyk; John Cheville; Guido Sauter; Peter J Wild; Robert Stoehr; Ferdinand Hofstaedter; Arndt Hartmann
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

7.  Deletion of the p16 and p15 genes in human bladder tumors.

Authors:  I Orlow; L Lacombe; G J Hannon; M Serrano; I Pellicer; G Dalbagni; V E Reuter; Z F Zhang; D Beach; C Cordon-Cardo
Journal:  J Natl Cancer Inst       Date:  1995-10-18       Impact factor: 13.506

8.  Urinary human polyomavirus and papillomavirus infection and bladder cancer risk.

Authors:  J Polesel; T Gheit; R Talamini; N Shahzad; O Lenardon; B Sylla; C La Vecchia; D Serraino; M Tommasino; S Franceschi
Journal:  Br J Cancer       Date:  2011-11-24       Impact factor: 7.640

9.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962

View more
  14 in total

Review 1.  Inverted urothelial papilloma: A review of diagnostic pitfalls and clinical management.

Authors:  Mary K Sweeney; Soroush Rais-Bahrami; Jennifer Gordetsky
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

2.  Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.

Authors:  Sumit Isharwal; Wenhuo Hu; Judy Sarungbam; Ying-Bei Chen; Anuradha Gopalan; Samson W Fine; Satish K Tickoo; Sahussapont J Sirintrapun; Sana Jadallah; Florence L Loo; Eugene J Pietzak; Eugene K Cha; Bernard H Bochner; Michael F Berger; Gopa Iyer; David B Solit; Victor E Reuter; Hikmat Al-Ahmadie
Journal:  J Pathol       Date:  2019-04-22       Impact factor: 7.996

3.  Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.

Authors:  Andi K Cani; Daniel H Hovelson; Andrew S McDaniel; Seth Sadis; Michaela J Haller; Venkata Yadati; Anmol M Amin; Jarred Bratley; Santhoshi Bandla; Paul D Williams; Kate Rhodes; Chia-Jen Liu; Michael J Quist; Daniel R Rhodes; Catherine S Grasso; Celina G Kleer; Scott A Tomlins
Journal:  Mol Cancer Res       Date:  2015-01-15       Impact factor: 5.852

4.  HRAS-driven cancer cells are vulnerable to TRPML1 inhibition.

Authors:  Jewon Jung; Kwang-Jin Cho; Ali K Naji; Kristen N Clemons; Ching On Wong; Mariana Villanueva; Steven Gregory; Nicholas E Karagas; Lingxiao Tan; Hong Liang; Morgan A Rousseau; Kelly M Tomasevich; Andrew G Sikora; Ilya Levental; Dharini van der Hoeven; Yong Zhou; John F Hancock; Kartik Venkatachalam
Journal:  EMBO Rep       Date:  2019-02-20       Impact factor: 8.807

5.  Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands.

Authors:  Koshiro Nishimoto; Scott A Tomlins; Rork Kuick; Andi K Cani; Thomas J Giordano; Daniel H Hovelson; Chia-Jen Liu; Aalok R Sanjanwala; Michael A Edwards; Celso E Gomez-Sanchez; Kazutaka Nanba; William E Rainey
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-03       Impact factor: 11.205

6.  Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.

Authors:  Brittny N Tillman; Megan Yanik; Andrew C Birkeland; Chia-Jen Liu; Daniel H Hovelson; Andi K Cani; Nallasivam Palanisamy; Shannon Carskadon; Thomas E Carey; Carol R Bradford; Scott A Tomlins; Jonathan B McHugh; Matthew E Spector; J Chad Brenner
Journal:  Head Neck       Date:  2016-02-05       Impact factor: 3.147

7.  Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.

Authors:  Daniel H Hovelson; Andrew S McDaniel; Andi K Cani; Bryan Johnson; Kate Rhodes; Paul D Williams; Santhoshi Bandla; Geoffrey Bien; Paul Choppa; Fiona Hyland; Rajesh Gottimukkala; Guoying Liu; Manimozhi Manivannan; Jeoffrey Schageman; Efren Ballesteros-Villagrana; Catherine S Grasso; Michael J Quist; Venkata Yadati; Anmol Amin; Javed Siddiqui; Bryan L Betz; Karen E Knudsen; Kathleen A Cooney; Felix Y Feng; Michael H Roh; Peter S Nelson; Chia-Jen Liu; David G Beer; Peter Wyngaard; Arul M Chinnaiyan; Seth Sadis; Daniel R Rhodes; Scott A Tomlins
Journal:  Neoplasia       Date:  2015-04       Impact factor: 5.715

8.  Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.

Authors:  Andi K Cani; Moaaz Soliman; Daniel H Hovelson; Chia-Jen Liu; Andrew S McDaniel; Michaela J Haller; Jarred V Bratley; Samantha E Rahrig; Qiang Li; César A Briceño; Scott A Tomlins; Rajesh C Rao
Journal:  Mod Pathol       Date:  2016-04-22       Impact factor: 7.842

9.  Intra-tumor genetic heterogeneity in rectal cancer.

Authors:  Karin M Hardiman; Peter J Ulintz; Rork D Kuick; Daniel H Hovelson; Christopher M Gates; Ashwini Bhasi; Ana Rodrigues Grant; Jianhua Liu; Andi K Cani; Joel K Greenson; Scott A Tomlins; Eric R Fearon
Journal:  Lab Invest       Date:  2015-11-16       Impact factor: 5.662

10.  Mutant HRAS as novel target for MEK and mTOR inhibitors.

Authors:  Michael K Kiessling; Alessandra Curioni-Fontecedro; Panagiotis Samaras; Kirstin Atrott; Jesus Cosin-Roger; Silvia Lang; Michael Scharl; Gerhard Rogler
Journal:  Oncotarget       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.